2017 American Transplant Congress
Comparison of Locoregional Therapies for Hepatocellular Carcinoma in Liver Transplant Recipients.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
Background: Locoregional therapies (LRT) have been employed in patients with hepatocellular carcinoma (HCC) to halt tumor progression and prevent waitlist drop out, as well as…2017 American Transplant Congress
Alemtuzumab Induction Is Associated with a Lower Incidence of BK Virus Nephropathy Compared with IL2RA Induction.
Renal Medicine, West London Renal and Transplant Centre, London, United Kingdom
Introduction:BK polyoma virus associated nephropathy [BKVAN] is a major cause of allograft dysfunction and graft loss occurring in up to 10% of kidney allograft recipients…2017 American Transplant Congress
Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study.
Paris Translational Research Center for Organ Transplantation, Paris, France
There is a marked heterogeneity in AMR patients' prognosis after SOC treatment including plasma exchange (PE) and intravenous immunoglobulins (IVIG). We investigated whether a composite…2017 American Transplant Congress
Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?
Introduction: The impact of HLA-DP de novo donor specific antibodies (dDSA) to lung transplantation (LT) is poorly understood. This study analyzed the association of timely…2017 American Transplant Congress
Renal Transplant Recipients with Indication for Antiplatelet Therapy: Increased Risk for the Allograft?
General Visceral and Transplantation Surgery, University Hospital, Essen, Germany
Background Antiplatelet therapy is common in patients on the waiting list for kidney transplantation increasing the risk for perioperative blood loss. This study evaluates the…2017 American Transplant Congress
Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.
Acute rejection rates and short-term graft survival have improved substantially as a result of advances in immunosuppression (IS), though longer-term graft survival rates have improved…2017 American Transplant Congress
Shared Decision Aid to Decipher Long-Term Treatment Risks for End Stage Renal Disease Patients.
Kidney transplantation is the preferred treatment for end stage renal disease (ESRD) compared to dialysis. The incidence of ESRD continues to increase while the gap…2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…2017 American Transplant Congress
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.
Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA
Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…2017 American Transplant Congress
Improved Outcome of Kidney Transplants by Donor Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes.
Introduction: De novo donor-specific HLA antibodies (dnDSA) are recognized as a risk factor for graft loss. Determinants of DSA specificity are generated via the indirect…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 113
- Next Page »